ACE2 News and Research

RSS

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021

A review of drugs harmful in COVID-19

In a new study, researchers investigate a number of drugs that are believed to potentially worsen outcomes in patients with COVID-19.

26 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

How SARS-CoV-2 spike binds to multiple host receptors

Researchers from the Genos Glycoscience Research Laboratory in Croatia have recently investigated the sites that the S protein is capable of binding with.

23 Sep 2021

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19.

23 Sep 2021

Long-term effects of COVID-19 in children

A recent preprint deals with the incidence and importance of long COVID in children.

23 Sep 2021

Antibody kinetics in recovered COVID-19 patients

Researchers from Tel Aviv University have been examining the kinetics of antibodies in recovered COVID-19 patients.

23 Sep 2021

Study reveals why SARS-CoV-2 is more infectious than SARS-CoV-1

Researchers from China and Canada recently combined structural data obtained from cryo-EM and structure prediction and constructed bottom-up Martini coarse-grained models of intact envelopes of SARS-CoV and SARS-CoV-2.

22 Sep 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

In a recent study, RBD produced in various cell types are characterized in-depth, comparing their applicability for future COVID-19 research.

21 Sep 2021

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

The scientists assessed epidemiological data from March to December 2020 from the CDC to investigate the prevalence of COVID-19 disease among different age groups.

21 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

Neurokinin-1 receptor: a potential drug target for the treatment of COVID-19

An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.

21 Sep 2021